BRIEF published on 08/20/2024 at 07:05, 3 months 1 day ago SKAN Group Reaches Its Targets in the First Half of 2024 Profitability Net Sales Growth Order Intake Half-year Results SKAN Group
PRESS RELEASE published on 08/20/2024 at 07:00, 3 months 1 day ago SKAN Group reaches its targets in the first half of 2024 SKAN Group AG achieves targets with net sales growth of 17.2% and EBITDA increase of 15.7% in the first half of 2024. Strong order intake and backlog, confirming guidance for full year Net Sales Growth Order Intake EBITDA Increase Guidance SKAN Group
BRIEF published on 05/31/2024 at 07:05, 5 months 21 days ago SKAN Increases Stake in Aseptic Technologies to 90 Percent Pharmaceutical Industry Stake Increase SKAN Aseptic Technologies AT-Closed Vial®
PRESS RELEASE published on 05/31/2024 at 07:00, 5 months 21 days ago SKAN increases stake in Aseptic Technologies to 90 percent SKAN Group AG increases its stake in Aseptic Technologies to 90%, reinforcing strategic importance. Aseptic Technologies specializes in AT-Closed Vial® Technology for cell and gene therapy applications Pharmaceutical Industry Stake Increase SKAN Group AG Aseptic Technologies AT-Closed Vial® Technology
BRIEF published on 05/07/2024 at 18:05, 6 months 13 days ago SKAN Group AG's Annual General Meeting: Unanimous Approval of Proposals, Beat Lüthi Elected Chairman Annual General Meeting Shareholder Approval Dividend SKAN Group AG Chairman Election
PRESS RELEASE published on 05/07/2024 at 18:00, 6 months 13 days ago Annual General Meeting of SKAN Group AG approves all pro-posals and elects Beat Lüthi as Chairman SKAN AG Annual General Meeting approves all proposals and elects Beat Lüthi as Chairman. Distribution of CHF 0.35 dividend per share approved, next AGM on 5 May 2025 Board Of Directors Annual General Meeting Dividend Distribution SKAN AG Beat Lüthi
BRIEF published on 03/26/2024 at 07:05, 7 months 26 days ago SKAN Group Announces Strong Financial Performance in 2023 with Increased Sales and Margins Financial Performance EBITDA Margin Biopharmaceutical Industry Annual Report 2023 SKAN Group
PRESS RELEASE published on 03/26/2024 at 07:00, 7 months 26 days ago SKAN with higher sales and margin in 2023 SKAN Group AG achieved higher sales and margin in 2023, exceeding communicated financial targets. Strategic initiatives on track with positive outlook for 2024 2023 Strategic Initiatives SKAN Group AG Higher Sales Margin
PRESS RELEASE published on 08/22/2023 at 07:00, 1 year 2 months ago SKAN Group demonstrates operational strength
PRESS RELEASE published on 05/26/2023 at 17:45, 1 year 5 months ago SKAN Group AG informs about the ongoing investigation of the Office of the Attorney General of Switzerland
Published on 11/21/2024 at 14:15, 5 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 20 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 20 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 20 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 4 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 5 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 1 hour 45 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 22 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 35 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 35 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
